On ECHEMI
Home > Drugs > Delirium syndrome
Delirium syndrome
Delirium syndrome is a group of syndromes characterized by widespread cognitive impairment, especially impaired consciousness. It is often caused by diffuse, temporary poisoning infection or metabolic disorder in the brain. Because it often occurs in poisoning infection, brain trauma and other diseases with acute onset, short course and rapid development of lesions, it is also called acute brain syndrome or acute confusional state. Delirium syndrome is the most common mental disorder in general hospitals, accounting for about 5% to 15% of internal and surgical patients, and most of them can recover. The following six types of patients are more likely to develop delirium: ① the elderly, ② children, ③ after heart surgery, ④ burns, ⑤ brain damage, and ⑥ drug dependence. Recently, two general hospitals abroad conducted an epidemiological study and found that 30% and 50% of the elderly aged 70 and over showed signs of delirium, respectively. However, because most elderly patients with physical diseases often stay at home for treatment when they have mild mental confusion, the incidence of delirium in the elderly appears to be much higher than generally estimated.
  • Site of disease:

    psychology
  • Infectious :

    Not contagious
  • Frequent population:

    Elderly patients
  • Related symptoms:

    Touching the void syndrome Intelligence decline Drug dependence Cognitive dysfunction Confusion
  • Concurrent disease:

Related Drugs
Ambroxol Hydrochloride Capsules
Indication: Used to thin sticky phlegm.
Manufacturer:

Anhui Pioneer Pharmaceutical Co., Ltd.

Ambroxol Hydrochloride and Glucose Injection
Indication: 1. Suitable for acute and chronic respiratory diseases accompanied by abnormal sputum secretion and poor sputum removal function, such as acute exacerbation of chronic bronchitis, asthmatic bronchitis, bronchiectasis and bronchial asthma; 2. Preventive treatment of postoperative pulmonary complications; 3. Treatment of premature infants and newborns with infant respiratory distress syndrome (IRDS).
Manufacturer:

Shijiazhuang No.4 Pharmaceutical Co., Ltd.

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.